Gilead developing tablet formulation of COVID drug remdesivir - CNBC
AlexSava/E+ via Getty Images


Gilead (GILD
+1.0%) is testing a tablet form of its COVID-19 drug Veklury (remdesivir), CNBC reports, adding it is in early stages.
The drug is currently only available as an injection.
Gilead was pursuing an inhaled version of remdesivir, but abandoned those plans in July 2021.

Remdesivir data released in September showed that the IV version cut the hospitalization risk in at-risk COVID patients by 87%.
Read why Seeking Alpha contributor Oyat believes that Veklury sales are set to increase.